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TSLP Directly Interacts with Skin-Homing Th2 Cells
Highly Expressing its Receptor to Enhance IL-4
Production in Atopic Dermatitis
Kazuki Tatsuno1, Toshiharu Fujiyama1, Hayato Yamaguchi1, Michihiko Waki1 and Yoshiki Tokura1
Thymic stromal lymphopoietin (TSLP) is overtly expressed on skin lesions of atopic dermatitis (AD), and the
initiative role of TSLP-activated DCs in AD has gained much attention in the past few years, while its actions on
other immune cells such as T cells have been given less notice. We aimed to clarify whether TSLP receptor
(TSLPR) is expressed on certain populations of T cells and whether TSLP possesses the capability to directly
interact with T cells from AD patients. Peripheral lymphocytes from 51 AD patients are analyzed by ﬂow
cytometry, and ex vivo experiments using peripheral blood and lesional skin-derived T cells were conducted.
TSLPR expression was deﬁned to CD4+ T cells, and CD4+CCR4+CXCR3−CCR7−CCR10+CLA+ T cells in AD patients
exhibited enhanced TSLPR expression. The frequency of TSLPR+CD4+ T cells correlated with disease activity.
CD4+ T cells from AD patients directly interacted with TSLP to produce a higher amount of IL-4 than those from
normal subjects, and this action was attenuated with anti-TSLPR antibody. The importance of IL-4 in the induction
of TSLPR expression was found in AD T cells. Our ﬁndings indicate that T cells from AD patients possess strong
potential to directly interact with TSLP to promote Th2 response.
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INTRODUCTION
Atopic dermatitis (AD) is a common chronic skin disorder,
with relapsing eczematous skin inﬂammation often accom-
panying severe pruritus (Bieber, 2008). In its pathogenesis,
interplay between several factors, such as altered barrier
function, intense pruritus/scratching, immunological distur-
bance, and sweating, contributes to the disease formation
(Koga et al., 2008; Kabashima, 2013; Yamaguchi et al., 2013).
Amongst the numerous elements involved in the development
of this allergic skin disorder, thymic stromal lymphopoietin
(TSLP) is recognized as a key epithelium-derived cytokine
participating in the initiation of Th2 immune response
(Soumelis et al., 2002; Takai, 2012).
High expression of TSLP is seen in the keratinocytes of AD
lesions (Soumelis et al., 2002). TSLP is a potent activation
factor of dendritic cells (DCs), capable of inducing high
expression of co-stimulatory molecules on DCs, triggering the
production of Th2-attracting chemokines such as CCL17/
TARC and CCL22/MDC, and induce Th2 differentiation
through OX40L upregulation on these cells (Ito et al., 2005).
Importance of TSLP–TSLPR signaling in skin DCs under
epicutaneous sensitization with protein antigens has also
been detailed, which depicts the role of TSLP in the
development of AD (Nakajima et al., 2012). Also, in an
allergen sensitization model, TSLP is produced in the skin but
not in the draining lymph nodes, suggesting that TSLP acts on
skin-resident cells rather than cells residing in the lymph
nodes to promote allergen sensitization (Larson et al., 2013).
Collectively, these studies depict the initiative role of TSLP in
inducing Th2 immune response in allergic skin reaction via its
function on DCs in skin environment.
On the other hand, direct role of TSLP on T cells has also
been explored to a lesser extent, mainly through murine
models. TSLP has been shown to enhance proliferation and
cytokine secretion levels through direct interaction with
murine T cells (Al-Shami et al., 2005; Omori and Ziegler,
2007; He et al., 2008; Kitajima et al., 2011). Recently, it has
been demonstrated that TSLP enhances the proliferation of
activated CD4+ and CD8+ T cells in humans (Rochman
et al., 2007; Akamatsu et al., 2008), indicating that TSLP can
directly interact with TCR-activated human T cells, and
possesses strong ability to enhance the proliferative activity.
Interestingly, the expression of TSLP receptor (TSLPR) is
usually not detected on resting T cells in human PBMCs,
but TCR stimulation can induce TSLPR expression, suggesting
that the induced TSLPR expression on T cells is essential
in human TSLP-T-cell interaction seen in these previous
experiments.
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In the present study, we focus on the activity of TSLP on
T cell, an immunocompetent cell essential in the form-
ation of inﬂammatory reaction in AD. We demonstrate that
CD4+ T cells from AD patients show high expression from
these patients reveal the importance of IL-4 in the induction of
TSLPR expression on human T cells. T cells from patients
interact directly with TSLP to induce strong Th2 response, thus
highlighting the role of TSLP-T-cell interaction in the
formation of Th2-biased cytokine milieu in AD.
RESULTS
High TSLPR expression on circulating CD4+ T cells in AD
patients
PBMCs from 51 AD subjects and 9 healthy individuals were
studied. Figure 1 shows representative ﬂow cytometric data of
AD patient’s PBMCs with high TSLPR expression. Lymphocyte
and monocyte fractions were gated for analysis (Figure 1a). As
expected from previous reports, only minimal expression of
TSLPR was conﬁrmed on PBMCs of normal individuals
(Figure 1b). However, the receptor expression was highly
enhanced in circulating PBMCs of AD patient (Figure 1b).
TSLPR expression was mainly seen on CD4+ T cells, while
CD3−CD11c+ (DCs), CD3dimCD14+ (monocytes), CD3−
CD20+ (B cells), and CD3−CD56+ (NK cells) demonstrated
minimal TSLPR positivity in AD patients (Supplementary
Figure 1 online).
The overall frequency of TSLPR expression on CD4+ T cells
from AD patients was signiﬁcantly higher (0.62%) than
normal healthy individuals (0.046%) (Figure 1c). PBMCs from
patients with psoriasis were also analyzed showing slight
elevation of TSLPR bearing CD4+ T cells (0.17%), but no
signiﬁcant difference was seen between psoriasis patients and
normal subjects. TSLPR positivity on CD4+ T cells of other
skin disorders such as urticaria and pruritus (TSLPR positivity
0.03 and 0.16%, respectively) was also examined, but AD
patients demonstrated greater receptor possession in
comparison.
We evaluated the immunophenotype of TSLPR-expressing
T cells in AD patients. Figure 1d is a representative data
from an AD patient. Lymphocyte fraction was gated for
evaluation. TSLPR-expressing cells co-expressed CCR4,
CCR10, and CLA and were negative for CXCR3, CCR7,
and CD45RA. CCR4 positivity and CXCR3 negativity
indicate that TSLPR-expressing cells are most likely to be
Th2 cells, and to some extent, regulatory T (Treg) and Th17
cells as these cells also express CCR4. CCR10 and CLA
positivity implies their skin-homing capacity, and CCR7 and
CD45RA negativity suggests that these cells are differentiated
memory effector cells. FoxP3 expression was also evaluated
(Figure 1e), and on average, 24.2% of TSLPR-expressing
CD4+ T cells showed Treg phenotype as deﬁned by CD25+
FoxP3+ cells.
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Figure 1. High TSLP receptor (TSLPR) expression on circulating CD4+ T cells in AD patients. Blood samples from atopic dermatitis (AD) patients and normal
healthy individuals were collected for ﬂow cytometric analysis. (a) Lymphocyte and monocyte fractions were gated for analysis. (b) Representative TSLPR
expression on CD4+ T cells in normal and AD patient samples. (c) Frequency (%) of TSLPR-expressing CD4+ T cells in PBMCs of normal (n= 7) and AD patient
(n= 51) samples. *Po0.005. (d) Immunophenotype of TSLPR-expressing cells in AD patient PBMCs. (e) FoxP3 expression of CD4+TSLPR+ T cells. These are data
from a representative AD patient expressing high TSLPR expression.
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Frequency of circulating TSLPR+CD4+ T cells correlates with
serum CCL17/TARC and IgE levels and eosinophil count
The clinical settings of the AD patients analyzed in this study
ranged from moderate to severe condition, and correspond-
ingly, TSLPR expression level on CD4+ T cells varied amongst
these patients. Analysis of 51 AD patients showed that TSLPR
expression level on circulating CD4+ T cells was higher in
those who had elevated serum TARC levels (ρ40.5). Serum
CCL17/TARC is an effective biomarker to assess AD, since
they often precisely reﬂect the acute Th2 inﬂammatory
condition (Kakinuma et al., 2001; Shimada et al., 2004).
Patients with high blood eosinophil count and serum IgE level
showed moderate correlation with the TSLPR expression on
circulating CD4+ T cells (0.54ρ40.2), while SCORAD and
itching scale (VAS) did not show signiﬁcant correlation
(ρo0.2 ) in this study (Figure 2a).
Change in the receptor expression before and after
treatment was additionally examined. Four in-patient AD
individuals with moderate to severe symptoms were selected
for this study. Patients were treated for ~ 2 weeks with basic
treatments including oral antihistamine medication, hygiene
control and corticosteroid ointments. UV treatment, oral
corticosteroids or cyclosporins were not administered in these
subjects. Circulating TSLPR+CD4+ T cells showed signiﬁcant
decrease after the treatment along with the improvement in
serum CCL17/TARC level (Figure 2b), indicating that TSLPR
expression on circulating CD4+ T cells correspond to the
disease severity.
TCR stimulation and IL-4 enhance TSLPR expression on CD4+
T cells
Previous reports denote TCR as key factor in the induction of
TSLPR on human T cells, but this does not explain well the
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Figure 2. Frequency of circulating TSLPR+CD4+ T cells correlates with serum CCL17/TARC, IgE levels and eosinophil count. (a) Frequency of circulating CD4+
TSLPR+ T cells in atopic dermatitis (AD) patients was compared with clinical parameters. For each analyzed patient, the clinical data use for analysis were
ascertained on the same day that ﬂow cytometry was performed, so that all parameters reﬂect the condition of each patient at one single time point. Spearman’s
rank correlation coefﬁcient analysis was used for statistical comparison of frequency of circulating CD4+TSLPR+ T cells with AD clinical markers. ρ40.5 signify
high correlation, and 0.54P40.2 show moderate correlation. (b) Comparison of serum CCL17/TARC and circulating TSLPR+CD4+ T cells in in-patient AD
individuals (n=4) before and after 2-week treatment. Paired t-test *Po0.05.
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reason behind high TSLPR expression in AD patients, while
low with other inﬂammatory skin disorders. Since serum IL-4
is often elevated in these subjects, we investigated the role of
IL-4 in TSLPR expression in human CD4+ T cells.
CD4+ T cells isolated from AD patients were treated
with anti-CD3/CD28 microbeads in the presence or absence
of IL-2 or IL-4 (Figure 3a), and as previously described
(Rochman et al., 2007; Akamatsu et al., 2008), TSLPR
expression on T cells was achieved by TCR stimulation.
With IL-2 or without cytokine, this enhancement peaked on
day 6 of culture, but gradually declined thereafter (Figure 3b,
n=4). Interestingly, the addition of IL-4 to the culture further
accelerated and maintained the TSLPR expression, and this
effect was seen throughout the 14-day culture period (Figure
3a and b).
In addition, we cultured the isolated CD4+ T cells without
TCR stimulation. CD4+ T cells cultured without anti-CD3/28
microbeads showed minimal TSLPR expression. However,
when these cells were cultured under IL-4 stimulation, TSLPR
expression dramatically increased after day 10 of culture
(Figure 3c and d). Samples cultured under IL-2 supplementa-
tion only showed minimal response. Cell viability assessed by
anexin-5 and 7-AAD staining did not differ between these
groups in this culture period (data not shown).
TSLP upregulates CCR4 expression and promotes the
proliferation of IL-4-producing cells
Next, we investigated the effect of TSLP on TSLPR bearing
CD4+ T cells in these patients. Freshly isolated CD4+ T cells
from patients (n= 4) were cultured with recombinant human
(rh)TSLP. During the 14-day culture period, dramatic increase
in the frequency of CCR4+ cells was noticed (Figure 4a).
While this effect was also seen to a milder extent with samples
treated with rhIL-2 or rhIL-4, it was signiﬁcantly higher in
rhTSLP-treated samples (Figure 4b).
Since surface CCR4 expression is one of the chief cell
surface marker for Th2 cells, we examined the effect of TSLP
on cell proliferation, especially focusing on its inﬂuence on
IL-4-producing cells. CD4+ T cells from patients (n= 8) were
labeled with CFSE, followed by rhIL-4 or rhTSLP supple-
mented culture. CFSE dilution was monitored at day 14 of
culture. Cells cultured in medium only showed very low
proliferative activity, while samples treated with cytokines
showed active cell growth. Notably, samples treated with
rhTSLP demonstrated higher proliferative activity compared
with samples treated with rhIL-4 (Figure 4c). While the
proliferative action was not speciﬁc to IL-4-producing cells in
neither sample, the overall increase in IL-4-producing cells
was signiﬁcantly higher compared with samples treated with
rhIL-4 (Figure 4d).
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Figure 3. TCR stimulation and IL-4 enhance TSLPR expression on CD4+ T cells. Puriﬁed CD4+ T cells from atopic dermatitis (AD) patients (n=4) were cultured
with anti-CD3/CD28 microbeads stimulation with or without rhIL-2 or rhIL-4 for up to 14 days. TSLP receptor (TSLPR) expression on CD4+ T cells was assessed on
day 4, 6, 9, and 14. (a) Representative analysis data from day 4 and day 14. Frequency (%) and mean ﬂuorescence intensity (MFI) in parentheses. (b) Overall
TSLPR expression level (MFI) throughout the culture period. The values represent mean± SE. *Po0.05. (c) Cells were cultured for 14 days without TCR
stimulation with or without IL-2 or IL-4. Representative ﬂow cytometric data on day 14. (d) TSLPR expression between the three groups on day 14. The values
represent mean± SE *Po0.05.
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TSLP augments IL-4 production from activated CD4+ T cells
Data presented thus far demonstrate that TSLP directly and
strongly stimulates CD4+ T cells toward Th2 phenotype in
AD. Therefore, we assessed whether TSLP inﬂuences the
actual IL-4 productivity through direct interaction with CD4+
T cells in these patients. CD4+ T cells isolated from PBMCs of
AD patients (n= 34) and normal individuals (n= 9) were
cultured for 2 days in the presence or absence of rhTSLP, with
anti-CD3/CD28 microbeads stimulation. Supernatants were
collected and evaluated by CBA assay. Generally, CD4+
T cells from AD patients contain more Th2 cells compared
with normal samples, and therefore, basic IL-4 production
level is expected to be high. Hence we calculated the
enhanced cytokine production rate between samples with
and without TSLP activation, to clearly demonstrate the effect
of TSLP on CD4+ T cells of AD patients.
Production of IL-4 was enhanced by ~ 30% in CD4+ T cells
from AD patients in response to rhTSLP, while this enhance-
ment was not seen in samples from normal individuals
(Figure 5a). This was seen dose dependently (Figure 5b), and
anti-TSLPR antibody attenuated the IL-4 secretion enhance-
ment (Figure 5c), suggesting that TSLP–TSLPR interaction is
responsible for the effect.
CD4+ T cells isolated from skin-derived T cells expanded
from skin specimen also showed similar result. T cells were
expanded from skin biopsy specimens from AD patients,
psoriasis patients and normal skin in previously described
method (Hashizume et al., 2010). rhTSLP enhanced the
production of IL-4 by more than 50% in samples from AD,
and CD4+ T cells collected from the skin lesion of psoriasis
or normal skin showed signiﬁcantly less response.
(Supplementary Figure 2 online).
TSLP ampliﬁes the expressions of IL-4 receptor (IL-4R), IL-2
receptor (IL-2R) and γ-common receptor (γ-cR) on CD4+ T cells
We next investigated whether TSLP inﬂuences the sensitivity
of T cells to IL-4, by assessing the expression of IL-4 receptor
on TSLP stimulated CD4+ T cells. Isolated CD4+ T cells from
AD patients were cultured with or without rhIL-2, rhIL-4 or
rhTSLP, and during the 14-day culture period, the expression
levels of IL-4R, IL-2R, and γ-cR were analyzed. TSLP
enhanced these receptor expressions more efﬁciently than
IL-2 or IL-4 (Figure 6a and b), indicating TSLP’s capability to
amplify T cell’s responsiveness to IL-2 and IL-4.
DISCUSSION
The present study shows that TSLPR is strongly expressed on
circulating CD4+ T cells in AD patients. PBMCs from patients
with other inﬂammatory skin disorders also showed upregu-
lated TSLPR expression, but the extent of its expression was
much higher in AD patients. In vitro experiments using freshly
isolated CD4+ T cells from these patients showed strong
response toward TSLP, ﬁrmly suggesting that TSLP can
directly interact with T cells in speciﬁc disease setting
such as AD.
TSLPR-expressing cells co-expressed CCR4 and CLA,
denoting their effector memory type phenotype. Analysis of
TSLPR expression on in vitro differentiated effector T cells in
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Figure 4. Thymic stromal lymphopoietin (TSLP) upregulates CCR4 expression and promotes proliferation of IL-4-producing cells. CD4+ T cells from AD
patients (n=4) were cultured with rhIL-2, rhIL-4, or rhTSLP. CCR4 expression was evaluated on day 4, 6, 9, and 14. (a) Representative ﬂow cytometric data on
samples cultured with TSLP in each evaluated time point. (b) CCR4 expression throughout the culture period. The values represent mean± SE *Po0.05
**Po0.01. CD4+ T cells from AD patients (n=8) were labeled with CFSE and cultured with or without rhIL-4 or rhTSLP. On day 14, intracellular IL-4 staining was
performed. (c) Representative ﬂow cytometric data. Squares denote the percentage of proliferating IL-4-producing cells. (d) Proliferation of IL-4-producing cells
between samples treated with IL-4 and TSLP was compared. Wilcoxon t-test. *Po0.05. AD, atopic dermatitis.
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mice show high TSLPR expression on Th2 cells, and mild
to low expression on Th1 and Th17, respectively (Kitajima
et al., 2011), which is in agreement with our observation.
Meanwhile, strong CLA positivity seen on TSLPR-expressing
T cells implies their skin-homing property. Previously,
immunohistochemical study of allergen-challenged skin on
atopic subjects revealed that TSLPR-expressing cells were
CD11c+, and the receptor expression on CRTH2+ cells was
not observed (Corrigan et al., 2009). While we found
increment of TSLPR expression on Th2 cells, the receptor
positivity is limited to small percentage of T cells (0.6% in
PBMCs and 13% in skin-derived T cells), which may explain
the difﬁculty in direct conﬁrmation of TSLPR positivity on
Th2 cells through immunohistochemical analysis using tissue
sections. Nonetheless, the immunophenotype of TSLPR-
expressing CD4+ T cells prompts the speculation that TSLP-
reactive effector Th2 cells that home toward the skin lesion
may be involved in the formation of Th2 inﬂammatory
response in the skin.
TSLP exerts its effect via TSLPR, which forms a hetero-
dimeric receptor with IL-7 receptor α-chain. While TSLPR
expression is seen on DCs, only minimal receptor expression
is observed on resting T cells, and activation is necessary to
detect observable TSLPR on T cells (Ziegler and Liu, 2006; Lu
et al., 2009; He and Geha, 2010). The precise mechanism
behind TSLPR expression on T cells remains elusive to date. In
human T cells, TCR stimulation has been documented as key
factor in TSLPR expression (Rochman et al., 2007; Akamatsu
et al., 2008), and other stimulations such as TSLP, IL-7 and
IL-5 did not induce or alter the expression of TSLPR on human
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Figure 5. Thymic stromal lymphopoietin (TSLP) augments IL-4 production
from activated CD4+ T cells. CD4+ T cells from atopic dermatitis (AD) patients
and normal individuals were TCR stimulated with or without rhTSLP or anti-
TSLPR antibody. Supernatants were collected and IL-4 concentration was
measured. Enhancement in IL-4 production by TSLP (%)= (IL-4 production
with TCR stimulation and TSLP (with or without anti-TSLPR Ab)—IL-4
production with TCR stimulation alone)/(IL-4 production with TCR stimulation
alone)× 100. (a) Comparison between AD (n= 23) and normal (n=7) samples.
rhTSLP (50 ng/ml). Mean± SE *Po0.05. (b) CD4+ T cells from patients
(n= 5) treated with varying TSLP concentration (0.1 ng ml−1, 5 ng ml−1,
25 ngml−1, 250 ngml− 1 rhTSLP). (c) CD4+ T cells from patients (n=5) treated
with rhTSLP (5 ng ml−1) with or without anti-TSLPR antibody (20 ugml−1).
*Po0.01.
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Figure 6. Thymic stromal lymphopoietin (TSLP) amplify IL-4 receptor (IL-4) receptor, IL-2 receptor (IL-2) receptor and γ-common receptor expression (γ-cR)
on CD4+ T cells. Isolated CD4+ T cells from atopic dermatitis (AD) patients (n= 5) were cultured with or without IL-2, IL-4 or TSLP, and during the 14-day culture
period, expression levels of IL-4R, IL-2R, and γ-cR were analyzed through FACS analysis on day 4, 6, 9, and 14. (a) Representative data at day 14 of culture.
Number in parenthesis signifying MFI. (b) The overall expression level of IL-4R, IL-2R, and γ-cR expression level at each evaluation period. The values represent
mean± SE *Po0.05 **Po0.01.
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CD8+ T cells (Akamatsu et al., 2008). In our study, activated
CD4+ T cells treated with IL-4 demonstrated further enhance-
ment in TSLPR expression compared with TCR-activated
CD4+ T cells without IL-4 supplementation. Furthermore,
prolonged IL-4 exposure prompted TSLPR expression in CD4+
T cells even without TCR stimulation, while this effect was not
seen in IL-2 supplemented samples, suggesting the rather
speciﬁc effect of IL-4 on TSLPR upregulation. These ﬁndings
imply that presence of IL-4 in inﬂammatory settings or chronic
elevation in IL-4 seen in AD may direct to enhancement in
TSLPR expression in human CD4+ T cells. This observation is
in accordance with previous ﬁnding using animal model, in
which IL-4 treatment was shown to increase TSLPR expression
on mice Th2 cells (Kitajima et al., 2011).
Previous studies using mouse models have shown that TSLP
induces the proliferation of Th2 cells, and modestly of Th1 or
Th17 cells. This proliferative action was reduced in Stat6− /−
Th2 cells, indicating that TSLP-mediated proliferation is
enhanced through an IL-4-Stat6 pathway (Kitajima et al.,
2011). Intriguingly, TSLP can directly act on naive CD4+
T cells in mice to induce strong IL-4 gene transcription and
subsequently, the production of IL-4, thereby creating a Th2
differentiating cytokine milieu in the absence of exogenous
IL-4 (Omori and Ziegler, 2007).
In regard to human T cells, TSLP induces rapid Stat5
activation on human CD4+ T cells, and enhances the
proliferation of TCR-activated CD4+ T cells (Rochman et al.,
2007). Likewise, strong proliferative action induced by TSLP
was evident in our study. Interestingly, pre-activation with
TCR stimulation was not a prerequisite in CD4+ T cells from
AD patients, and the high TSLPR expression on CD4+ T cells
in these patients may be the predisposing factor behind this
observation. In addition, strong enhancement in CCR4
expression and marked increase in proliferation of IL-4-
producing cells was also achieved by simply supplementing
TSLP to the culture, indicating the propensity of CD4+ T cells
in these patients to TSLP stimulation.
Furthermore, TSLP interacted with activated CD4+ T cells
from AD patients to amplify Th2 reaction, as seen in by the
increase in IL-4 production. This effect was prominent with
CD4+ T cells from AD patients, but not with that of normal
individuals. Moreover, the dose-dependent effect and
attenuation by TSLPR blockade collectively points to the
importance of speciﬁc signaling through TSLPR in TSLP-T-cell
interaction.
TSLP was also shown to accentuate IL-2R and IL-4R on
CD4+ T cells from AD patients. TSLP is known to elevate
IL-2R expression on T cells (Rochman et al., 2007), and
increase in IL-2R was also noted in TSLP-treated CD4+ T cells
in our experiment. On the other hand, type I cytokine such as
IL-2 is known to enhance IL-4R expression by activating
STAT5A and STAT5B to promote increased transcription of
the Il4Ra gene (Rochman et al., 2009), and surprisingly, IL-4R
expression on these cells were augmented by TSLP as well,
indicating that TSLP may augment the cell’s sensitivity to IL-4.
By amplifying the receptors respectively, a positive bilateral
collaboration may exist between TSLP and IL-4 in human
T cells.
In summary, this study provides evidence of increased
TSLPR bearing T cells in AD patients, which respond strongly
to TSLP to augment Th2-biased reaction. TSLP promotes
proliferation of IL-4-producing cells and increase IL-4 produc-
tion from CD4+ T cells in AD. Expression of TSLPR on T cells
was vital in T cells response to TSLP, suggesting TSLPR to be a
potential therapeutic target in the treatment of allergic disorders
such as AD in future. Furthermore, TSLP induced upregulation
of IL-4R, and alternatively, IL-4 increased TSLPR on CD4+
T cells, suggesting a possible positive feedback loop mechan-
ism between TSLP and IL-4, which may be an underlining
factor in the formation of persistent Th2 reaction in AD.
MATERIALS AND METHODS
Patients and peripheral blood samples
Enrolled were 51 AD subjects, both outpatients and inpatients,
treated in our hospital from October 2013 to April 2015, and 9
healthy individuals. The majority of the patients were extrinsic type
AD with high serum IgE levels. PBMCs obtained by standard Ficoll–
Hypaque method PBMCs were analyzed by ﬂow cytometry
immediately after collection. The study was conducted in accor-
dance with the Declaration of Helsinki Principles, and approved by
the ethics committee of Hamamatsu University School of Medicine,
with written informed consent obtained from the participants.
Flow cytometry
PBMCs were stained with ﬂuorescein isothiocyanate (FITC)-, phyco-
erythrin (PE)-, peridinin chlorophyll (PerCP)-, or allophycocyanin
(APC) conjugated anti-CD3-CD4-CD8-CD11c-CD14-CD20-CD123-
HLA-DR-CD56-CCR4-CXCR3-CLA-CCR10-CD45RA-CCR7-TSLPR-
CD25-CD127-CD124-CD132 mAb, (BD Bioscience, San Diego,
CA and Biolegend, San Diego, CA). After incubation for 30 minutes
at 4 °C with mAb or control isotype-matched controls, cells were
washed twice and analyzed on FACSCanto (BD Bioscience).
CD4+ T cell isolation and culture conditions
CD4+ T cells from AD patients were puriﬁed through magnetic cell
sorting (negative selection) (Miltenyi Biotec, San Diego, CA). Puriﬁed
cells were cultured in cRPMI (2–5× 105 cells per ml) for up to
14 days with recombinant human IL-2 (50 Uml−1), IL-4 (100
ngml− 1), or rhTSLP (50 ngml−1) (R&D Systems, Minneapolis, MN)
with or without anit-CD3/CD28 Ab-coated microbeads (10 ul ml−1)
(Dynabeads Human T-activator CD3/CD28, Invitrogen Dynal AS,
Oslo, Norway). Half medium change was performed every 2 to 3 days.
Replenishing culture medium was supplemented with cytokine to
maintain equal concentration throughout the culture period.
PBMC stimulation with PMA and ionomycin
For intracellular cytokine staining, cells were stimulated with
10 ngml−1 PMA (Sigma-Aldrich, St. Louis, MO), 10− 6 M of
ionomycin (Wako Pure Chemical, Osaka, Japan) and 0.7 μl of
Golgistop (BD Bioscience) for 6 hours.
Proliferation assay with CFSE labeling
Isolated CD4+ T cells from AD patients were labeled with CFSE
(Cayman Chemical, Ann Arbor, MI) according to provider protocol.
Cells were cultured with or without rhIL-4 or rhTSLP supplementa-
tion, and CFSE dilution was monitored at day 14 of culture.
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CBA assay
CD4+ T cells freshly isolated from PBMCs or expanded skin-derived
T cells were seeded at a density of 5× 105 cells per ml in ﬂat-
bottomed 96-well plate, and stimulated with anti-CD3/28 Ab-coated
microbeads with or without rhTSLP or anti-TSLPR Ab (R&D Systems),
followed by 48 hour culture. Supernatants were collected and
cytokine concentration was measured by CBA assay.
Preparation of skin-derived lymphocytes
Skin specimens (half of 3mm punch biopsy) from AD patients (n=6),
psoriasis patients (n=8) and normal skin (n=12) were cultured in 5ml
cRPMI containing 50Uml−1 rIL-2 and 5ml anti-CD3/CD28 Ab-coated
microbeads in a 6-well culture plate for 2–3 weeks. Cultured cells were
replenished with the same medium containing rhIL-2 every 2–3 days,
and expanded cells were transferred to new wells appropriately. More
than 1×107 lymphocytes were produced in this method.
Statistical analysis
The statistical package R version 3.1.0 (The R Foundation for Statistical
Computing, Vienna, Austria) was used for the analysis. Spearman’s
rank correlation coefﬁcient analysis was used for the statistical
comparison of frequency of circulating CD4+TSLPR+ T cells with AD
clinical markers. Paired t-test was used to assess signiﬁcant differences
in the means between groups. For correlation analysis, ρ40.5 was
considered to signify high correlation, and 0.54ρ40.2 was con-
sidered to show weak correlation. Kruskall–Wallis test followed by
Steel–Dwass’s multiple comparisons post hoc test was applied for the
analysis of IL-4 production rate in skin-derived T cells.
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